TGTX Enterprise Value Over E B I T D A from 2010 to 2024
| TGTX Stock | USD 34.61 0.46 1.31% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 93.58066333 | Current Value 98.26 | Quarterly Volatility 35.94016421 |
Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 444.1 K, Interest Expense of 13.2 M or Total Revenue of 245.3 M, as well as many indicators such as Price To Sales Ratio of 9.86, Dividend Yield of 4.0E-4 or PTB Ratio of 15.86. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
TGTX | Enterprise Value Over E B I T D A |
Latest TG Therapeutics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of TG Therapeutics over the last few years. It is TG Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
TGTX Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | 8.40 | |
| Coefficient Of Variation | 427.74 | |
| Mean Deviation | 23.34 | |
| Median | (3.04) | |
| Standard Deviation | 35.94 | |
| Sample Variance | 1,292 | |
| Range | 118 | |
| R-Value | 0.51 | |
| Mean Square Error | 1,029 | |
| R-Squared | 0.26 | |
| Significance | 0.05 | |
| Slope | 4.10 | |
| Total Sum of Squares | 18,084 |
TGTX Enterprise Value Over E B I T D A History
About TG Therapeutics Financial Statements
TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 93.58 | 98.26 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.